Evaluation of WO2012037132 - a novel scaffold for selective JAK1 inhibition.
Novel 1-anilino-4-phenylphthalazine derivatives, compositions containing them, and their use as JAK1 inhibitors and for the treatment of cancer, inflammatory and autoimmune diseases are claimed. This represents a novel scaffold for JAK inhibitors and is highly distinct from the JAK1 inhibitors previously described, although the same scaffold has been employed in other kinase inhibitors.